Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
Improving Lives Through
Diagnostic and
Therapeutic Solutions
AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.
CANNABINOID RESEARCH
AXIM was one of the first
companies to identify the
potential therapeutic benefits
of cannabinoids
CLINICAL therapeutics
AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
Diagnostic Testing
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
AXIM Biotechnologies is a vertically integrated pharmaceutical research company focused on the development of diagnostic tests for the early detection of cancer, research on proprietary small molecules drugs that not only treat cancer but also block metastasis, and research of novel antibodies for therapeutic and diagnostic uses.
AXIM® Biotechnologies Expands Research Division and Announces Dr. Sergei Svarovsky as Chief Scientific Officer of Subsidiary Sapphire Biotech
SAN DIEGO – May 27, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today it has expanded its research division through...
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood
AXIM® Biotechnologies Files for Patent for Unique Biomarker for Early Detection of Cancer in Blood NEW YORK – May 18, 2020 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting...
AXIM® Biotechnologies Issues Update Letter to Shareholders
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that it has issued a letter...